Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment

Radiotherapy sensitizes unresponsive tumors to the antineoplastic activity of antibodies that target the inhibitory receptor CTLA-4 on T cells. One molecular mechanism accounting for this therapeutic synergy is the induction of NKG2D ligands on irradiated tumor cells. The fact that NKG2D receptors must be engaged for the elicitation of CD8+ T-cell antitumor responses has important clinical impl...

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors

Cancer immunotherapy with antibodies targeting immune checkpoints has demonstrated durable clinical benefit, though responses have not been universal and, in particular, not effective for tumors lacking preexisting lymphocytic infiltration. Oncolytic viruses (OV) have recently emerged as an important addition to the immunotherapy armamentarium, with promising activity seen in recent clinical tr...

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors

PURPOSE We have previously shown that supraoptimal signaling of high avidity T cells leads to high expression of PD-1 and inhibition of proliferation. This study was designed to see if this effect could be mitigated by combining a vaccine that stimulates high avidity T cells with PD-1 blockade. EXPERIMENTAL DESIGN We investigated the anti-tumor effect of a huIgG1 antibody DNA vaccine (SCIB1) ...

Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors.

The selection of nontumorigenic (turn'), highly immunogenic variants from four different tumorigenic but poorly immuno genic murine tumors by mutagen treatment and cloning is described. Several factors were found to determine the suc cessful nature of this selection procedure including: the nature of the tumor used; the nature of the mutagen; the number of mutagen treatments; and the time at wh...

Dendritic Cell-Tumor Fusion Vaccines Immunogenic Tumors by Immunization with Eliciting T Cell Immunity Against Poorly